The t(1;19) translocation in pediatric pre-B-cell acute lymphoblastic leukemia (ALL) fuses the genes, which encode the transcriptional activator E2A and homeobox pre-B-cell leukemia transcription factor 1 (PBX1), resulting in expression of the chimeric transcription factor E2A-PBX1. E2A-PBX1 can promote cell transformation both in vitro and in vivo; however, the mechanisms by which E2A-PBX1 contributes to malignancy merit further investigation. In the current work we report, for the first time, a physical and functional interaction between the SPT3-TAF II 31-GCN5L acetylase (STAGA) complex and E2A-PBX1. STAGA, and its acetyltransferase subunit GCN5, directly interacted with the E2A portion of E2A-PBX1. GCN5 acetylated E2A-PBX1 and increased the stability of E2A-PBX1 protein in cells. Moreover, the GCN5 inhibitor a-methylene-g-butyrolactone 3 (MB-3) decreased E2A-PBX1 acetylation and E2A-PBX1 protein levels in leukemic cells, indicating that GCN5 inhibitors have potential value as therapeutic agents for ALL. In addition, we show that the E3 ubiquitin ligase HDM2 potentiates the degradation of E2A-PBX1. We suggest that dynamic regulation of E2A-PBX1 protein levels in vivo has a fundamental role in ALL.
INTRODUCTION
Acute lymphoblastic leukemia (ALL) is the most common form of childhood leukemia, with an incidence of B3.4 per 100 000 individuals below the age of 15 in the United States. 1 Chromosomal translocations are an important mechanism that drives oncogenesis in leukemia. The gene E2A on chromosome 19 is involved in three well-defined structural chromosomal rearrangements, which occur in pediatric ALL. The t(1;19) (q23;p13.3) translocation is cytogenetically detectable in 5-6% of all pediatric ALL cases; however, it has a frequency of B23% in patients with pediatric pre-B ALL. 2 The t(1;19) (q23;p13.3) translocation event fuses the N-terminal transactivation domain of E2A to the homeodomain of pre-B-cell leukemia transcription factor 1 (PBX1), resulting in the chimeric transcription factor E2A-PBX1. E2A-PBX1 can induce cell transformation both in vitro and in vivo, 3 and the presence of the E2A-PBX1 protein in leukemic blasts from patients with pre-B-cell ALL is associated with a poor prognosis. 4 The E2A gene encodes two proteins, E12 and E47, generated through differential splicing of the E2A transcript, which are identical except for their basic helix-loop-helix DNA-binding regions. E2A has a central role in B-lymphopoiesis by participating in B-lineage determination, the development of pre-B cells from pro-B cells, recombination of immunoglobulin (Ig) H and IgL chain loci, and isotype switching in activated mature B-lymphocytes. B-cell development is severely impaired in E2A knockout mice, resulting in postnatal death. 5 As a transcription factor, E2A contains two N-terminal activation domains (AD1 and AD2) and a C-terminal DNA-binding domain. Both ADs of E2A are present in E2A-PBX1, and are essential for the transactivation function of the chimeric protein. 6 PBX1 is an important regulator of embryonic development; however, it is not normally expressed in the lymphoid compartment. PBX1 cannot activate transcription alone; rather it acts as a cofactor for HOX proteins, by forming HOX/PBX1 heterodimers to increase the DNA-binding specificity of HOX proteins. 7, 8 More than two decades have passed since the initial characterization of E2A-PBX1; however, the exact mechanisms by which this oncoprotein contributes to pre-B-cell ALL still remain elusive. One hypothesis is that E2A-PBX1 can activate the expression of HOX-PBX1 target genes, which are normally not expressed in the lymphoid compartment, by associating with HOX proteins( 3 and references within). Alternatively, the E2A-PBX1 homodimer may act as a dominant-negative molecule, which sequesters the cofactors required by E2A, thus repressing the expression of E2A target genes. Given the importance of E2A in various stages of lymphocyte differentiation and activation, a dominant-negative function for E2A-PBX1 seems a plausible explanation. Many of the genes that are specifically expressed in t(1;19) cell lines have been identified, of which E2a-Pbx1-activated gene in pre-B cells 1 (EB-1) and WNT16 have been suggested to be of particular importance in the development of leukemia. 9, 10 Although the t(1;19) chromosomal translocation is essential for leukemic transformation, it is most likely not sufficient for leukemia development alone, with the complexity of the affected signaling pathways and presumably secondary genetic alternations jointly contributing to the final malignant phenotype.
Acetylation of histone tails is an important post-translational modification, which has a major role in the unfolding of silenced chromatin. General control nonderepressible 5 (GCN5) and p300/ CBP-associated factor (PCAF) are highly homologous members of the (GNAT) superfamily of N-acetyltransferases, which are involved in histone acetylation. GCN5 and PCAF can function as subunits of at least two types of multiprotein complexes, the 700 kDa ADA two A-containing (ATAC) complexes and the 2 MDa complexes  SPT3-TAF II 31-GCN5L acetylase (STAGA), TATA-binding protein-free  TAF-containing complex (TFTC) and PCAF. 11,12 Although they were initially found to acetylate histones, subsequent studies have revealed GCN5 and PCAF also have multiple non-histone targets. Acetylation of numerous transcription factors by GCN5 and PCAF has been described, resulting in various effects, for example affecting DNA binding, protein-protein interactions, nuclear localization and protein stability. 13 Studies in yeast indicate that E2A mediates transcriptional activation via recruitment of the SPT-ADA-GCN5 acetylase (SAGA) complex, the yeast homolog of STAGA.
14 The SAGA complex interacts with the conserved LDFS motif of E2A. 15 Interestingly, it was recently demonstrated that E2A-PBX1 induces fibroblast proliferation in cell culture, and in similar manner to the other oncogenic properties of E2A-PBX1, this effect was dependent on the LDFS motif of E2A. 16 Direct acetylation of E2A by the functionally related histone acetyl transferases (HATs) p300 and CREB-binding protein (CBP) was first observed in vitro, and it was demonstrated that these HATs increased E2A-mediated transcriptional activity and promoted nuclear retention of E2A. 17 However, these investigations were performed with an E2A-isoform lacking the important N-terminal AD1. More recently it was reported that a conserved lysine at position 34 of the E2A AD1 is acetylated by CBP/p300, and acetylation of Lys34 was shown to promote binding of CBP/ p300, as well as E2A-mediated transcriptional activation. 18 Lys34 is in close proximity to the overlapping conserved LXXLL and LDFS motifs at amino-acid positions 16-23 of the E2A AD1 (see Figure 1b) . LXXLL can directly interact with the KIX domain (also called the CREB-binding domain) of CBP/p300. 19 Leu20, which constitutes the overlap between the LXXLL and LDFS motifs in the E2A AD1, is critical for the induction of leukemia by E2A-PBX1 in mice, 20 and the following D and F residues are required for E2A-PBX1-induced fibroblast proliferation, 16 demonstrating the importance of the LXXLL and LDFS motifs in pre-B-cell ALL.
Additionally, it was recently reported that E2A proteins enhance the HAT activity of CBP and p300, although the KIX domain of CBP is dispensable. 21 As lysine residues are not only modified by acetylation, but may also be the targets of ubiquitination, complex cross-talk mechanisms have been reported for the regulation of protein stability. Acetylation is thought to prevent protein ubiquitination and degradation, either through direct competition with ubiquitination for the same lysine residues, as reported for p53 and other important regulatory factors, or due to conformational changes or recruitment of other proteins, which may block the binding of E3 ubiquitin ligase. 22 The proto-oncogene human double minute-2 (HDM2) is an ubiquitin E3 ligase, which promotes autoubiquitination, as well as the ubiquitination of p53 and several other cellular proteins, which leads to their proteasomal degradation. HDM2 is upregulated in many human cancers, and its tumorigenic activity is thought be owing to its ability to target p53 for degradation. 23 In this study, we aimed to investigate whether post-translational modifications regulate E2A-PBX1 protein stability, as we hypothesized that post-translational modifications may contribute to the oncogenic potential of this chimeric protein in ALL. We report, for the first time, evidence of a direct physical interaction between E2A-PBX1 and the GCN5/STAGA complex, and we demonstrate that acetylation of E2A-PBX1 by GCN5 increases the protein level of E2A-PBX1 in ALL cells. We also show that E2A-PBX1 interacts with HDM2, which leads to ubiquitination and degradation of E2A-PBX1 in ALL cells.
MATERIALS AND METHODS

Constructs and cell lines
E2A-PBX1b cDNA was amplified by PCR and subcloned into pGEX4T3 (GE Healthcare, Little Chalfont, UK). E2A-PBX1a was subcloned from pGEX2T-E2A-PBX1a (provided by Dr DP LeBrun, Queens University, Kingston, ON, Canada) into pcDNA3.1 (Invitrogen, Carlsbad, CA, USA). HDM2 cDNA was amplified using PCR and subcloned into pcDNA3.1 þ / À FLAG-tag. S-labeled GCN5 and the bound proteins were analyzed by SDS-PAGE and autoradiography. The input represents 2% of the reticulate lysate with 35 S-labeled GCN5 used in each binding reaction.
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pGEX2T-E2A 1-483 was a kind gift of Dr DP LeBrun and pGEX-PBX1a and pGEX-PBX1b were gifts of Dr FB Hillgartner (West Virginia University, Morgantown, WV, USA). The expression plasmid pcDNA-FLAG-GCN5 was generously provided by Dr P Puigserver (Harvard Medical School, Boston, MA, USA), and the HA-p300 and HA-Ub expression plasmids were generously provided by Dr PA Cole (Johns Hopkins University School of Medicine, Baltimore, MD, USA and Dr D Bohmann (University of Rochester Medical Center, Rochester, NY, USA), respectively. The LDFS mutation (DF to AA) in E2A-PBX1 was introduced using QuickChange site-directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA) with the following primers:
Human embryonic kidney 293 (HEK-293) cells (ATCC, Manassas, VA, USA) were cultured in DMEM supplemented with 10% FBS and 1% penicillinstreptomycin. RCH-ACV cells (DSMZ, Braunschweig, Germany), 697 and REH cells (ATCC) were cultured in RPMI-1640 media supplemented with 10% FBS and 1% penicillin-streptomycin. FLAG-SPT3-expressing HeLa S cells (fh:SPT3 stable cell line) were cultured as previously described. 12 Patient samples
This study included leukemic cells from children with pre-B ALL. Informed consent was obtained from the parents, in accordance with the study approval conditions dictated by the local ethics committee (Karolinska Institutet, Stockholm, Sweden). The patients were diagnosed according to the World Health Organization classification 24 and the bone marrow sample contained more than 80% leukemic blasts, as established during routine diagnostic procedures using multiparameter FACS analysis, as previously described. 25 The t(1;19) E2A-PBX1 translocation was detected by fluorescence in situ hybridization using routine procedures at diagnosis. Mononuclear cells were isolated from bone marrow (taken at diagnosis) by centrifugation on a Ficoll/Hypaque (Lymphoprep, Oslo, Norway) gradient and cryopreserved in liquid nitrogen. Upon thawing, the leukemic cells were cultured ex vivo at an initial concentration of 1 Â 10 6 cells/ml in RPMI-1640 supplemented with 10% (v/v) heat-inactivated fetal calf serum, 2 mM L-glutamine and 50 mg/ml streptomycin/penicillin (Invitrogen). The cells were treated with 50 mM a-methylene-g-butyrolactone 3 (MB-3; SigmaAldrich, St Louis, MO, USA) for 14 h, and total protein was extracted using modified RIPA buffer (50 mM Tris-HCl pH 7.4, 150 nM NaCl, 1 mM EDTA, 1% NP-40 and 1% glycerol) containing protease inhibitor cocktail, phosphoSTOP (Roche, Basel, Switzerland), 1 mM orthovanadate and 1 mM DTT on ice for 20 min. Cell lysates were cleared by centrifugation and the proteins were subsequently analyzed by immunoblotting with the following antibodies: E2A-PBX1 (556021; BD Biosciences, Franklin Lakes, NJ, USA), E2A (E12/E47; 554199; BD Biosciences), GCN5 (sc-20698), Wnt16 (sc-271897), Pol II (sc-9001) and Tubulin (sc-5546; Santa Cruz Biotechnology, Santa Cruz, CA, USA).
Protein purification and protein-protein interaction assays
Glutathione S-transferase (GST)-tagged proteins were expressed in the Escherichia coli strain BL21 and purified using glutathione-Sepharose 4B (GE Healthcare, Buckinghamshire, UK) following the manufacturer's protocol. The STAGA complex was purified from the nuclear extracts of HeLa S cells, which stably express FLAG-HA-tagged SPT3, as previously described. 12 For the GST protein-protein interaction assays, B10 mg of each GSTtagged fusion protein was immobilized on glutathione-Sepharose beads (20 ml) and then incubated with purified STAGA complex ( Figure 2b ), HeLa nuclear extract (Figure 2d ) or HDM2 expressed by E. coli strain BL21, and affinity purified using Ni-NTA agarose ( Figure 4c ) in buffer A (50 mM TrisHCl, pH 7.3, 150 mM KCl, 0.1% NP-40, 0.2 mg/ml BSA, 1 mM PMSF and 1 mM DTT) for 4 h at 4 1C. The bound material was analyzed using SDSpolyacrylamide gel electrophoresis (PAGE) and immunoblotting using antibodies against TRRAP (ab73546), CDK11 (ab19393; Abcam, Cambridge, UK), ADA2 (sc-6651), GCN5 (sc-20698), SPT3 (sc-101157; Santa Cruz Biotechnology), and TAF31 (generously provided by Dr RG Roeder, Rockefeller University, New York, NY, USA). In the crosslinking assay (Figure 2e ), glutathione-Sepharose beads containing immobilized GST-E2A-PBX1 or GST were incubated with affinity-purified STAGA or HeLa nuclear extract. Beads were, according to previously described experimental, 26 washed five times with 1 ml buffer A (see above) and twice with 1 ml PBS, and incubated 3 min with dithiobis(succinimidylpropionate) (Thermo Fisher Scientific Inc, Rockford, IL USA) at a final concentration of 2.5 mM in 0.6 ml PBS. Beads were washed with 1 ml 50 mM Tris-HCl, pH 7.5 and incubated in 1 ml of 8 M urea for 30 min to dissociate non-crosslinked proteins. After three wash steps with 1 ml buffer A, beads were incubated with SDS sample buffer to reverse the crosslinking and eluted proteins were analyzed by SDS-PAGE and immunoblot.
In Figure 1e , GCN5 was labeled with [35S]-methionine using TNT reticulate lysates (Promega, Madison, WI, USA), according to the manufacturer's standard protocol. In vitro-translated GCN5 was incubated with glutathione-sepharose beads containing immobilized GST-E2A-PBX1, GST-E2A-PBX1-LDFSmutant (GST-E2A-PBX1-LAAS) or GST at 4 1C overnight in buffer A. After washing with buffer A, the bound material was subjected to SDS-PAGE and autoradiography.
In Figure 2c , the STAGA complex was incubated in buffer B (150 mM NaCl, 50 mM HEPES [pH 7.5], 10% glycerol, 0.1% Tween 20, 0.5 mM dithiothreitol, 1 mM PMSF) with GST-E2A-PBX1a and GST proteins bound to glutathione-sepharose beads for 2 h at 4 1C, the supernatant was removed and the beads were washed four times in buffer B. Liquid histone acetyltransferase (HAT) assay was performed essentially as previously described 14 and as follows; 1 mg of core histones were incubated with GST-E2A-PBX1a and GST bound to glutathione-Sepharose beads and 3 mM 3H-acetyl-CoA in 20 ml reaction volume in HAT buffer (50 mM Tris-HCl [pH 8.0], 50 mM KCl, 5% glycerol, 0.1 mM EDTA, 1 mM DTT, 1 mM PMSF, 10 mM sodium butyrate) at 30 1C for 1 h, and the reaction mixture was subjected to SDS-PAGE and fluorography.
The endogenous proteins E2A-PBX1, E2A and HDM2 were immunoprecipitated from RCH-ACV whole-cell extracts using antibodies against E2A-PBX1 (556021; BD Biosciences), E2A (E12/E47; 554199; BD Biosciences) and HDM2 (sc-965; Santa Cruz Biotechnology). The immunoprecipitated proteins were analyzed by western blotting using the antibodies indicated in Figure 4a .
In vivo protein acetylation assay HEK-293 cells were transfected with expression plasmids as indicated in the figures using TransIT-LT1 transfection reagent (Mirus Bio, Madison, WI, USA), 24 h after transfection the cells were treated with 500 nM trichostatin A (TSA), 10 mM nicotinamide and the GCN5 inhibitor MB-3 as indicated. The cells were harvested 40 h after transfection and lysed in 300 ml buffer C (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 1 mM DTT, 0.2 mM PMSF and Complete EDTA-free protease inhibitor (Pierce, Rockford, IL, USA). E2A-PBX1 was immunoprecipitated using an E2A-PBX1 specific antibody (556021; BD Biosciences) coupled to Protein G sepharose (Invitrogen) following the manufacturer's protocol, and analyzed by western blotting using the following antibodies: E2A-PBX1 (556021; BD Biosciences), Acetyl-lysine (ab-21623; Abcam), HA (sc-805; Santa Cruz Biotechnology), FLAG (F3165; Sigma-Aldrich) and GAPDH (AM-4300; Ambion/Life Technologies, Grand Island, NY, USA). The immunoreactive proteins were detected using enhanced chemiluminescence reagents (Super Signal West Pico, ThermoScientific/Pierce or ECL Advance, GE Healthcare). To investigate acetylation of endogenous E2A-PBX1 in RCH-ACV and 697 cells, the cells were treated with 10 mM TSA, 20 mM nicotinamide and 50 mM MB-3 for 16 h, and subsequently analyzed as above. REH cells were used as a negative control.
In vivo ubiquitination assay HEK-293 cells were transfected with expression plasmids as indicated in the figures. The cells were either cultured for 40 h and treated with 500 nM TSA, 10 mM nicotinamide and 3 mM MG132 (Calbiochem, La Jolla, CA, USA) for 16 h before harvesting (Figure 4d) , or cultured for 44 h and treated with 10 mM MG132 for 4 h before harvesting (Figure 4e ). E2A-PBX1 was immunoprecipitated and FLAG-PBX1 was affinity purified using M2-agarose (Sigma-Aldrich). Ubiquitination was analyzed by immunoblotting using the antibodies indicated in Figures 4d and e. Protein degradation assay RCH-ACV cells were treated for B20 h with MB-3 (Sigma-Aldrich), at the concentrations indicated in the figure legend, then the cells were harvested and lysed in buffer C. REH cells were transfected with expression plasmids by electroporation (Bio-Rad, Hercules, CA, USA), cultured for 20 h, harvested and degradation of the indicated proteins was analyzed by immunoblotting. For E2A-PBX1 half-life experiments RCH-ACV cells were pre-treated with 100 mM MB-3, 10 mM TSA and 20 mM nicotinamide for 2 h before treatment with 100 mg/ml cycloheximide (Sigma-Aldrich) at the times indicated in Figure 3f . HEK-293 cells were transfected with E2A-PBX1 and HDM2 expression plasmids and cycloheximide treatment was carried out 48 h post-transfection (Figure 4g ).
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RESULTS
E2A-PBX1 is acetylated by GCN5
The chimeric transcription factor E2A-PBX1 comprises amino acids 1-483 of E2A fused to either PBX1a or PBX1b (Figure 1a ). E2A-PBX1a is the most common form in pediatric pre-B ALL. 27 Previous reports have indicated that E2A is acetylated by the HATs p300 and CBP 17, 18 via a mechanism dependent on the E2A LXXLL motif. E2A also contains the STAGA (GCN5-containing) HAT complex binding motif LDFS (see Figure 1b) , which has been shown to be important for E2A-PBX1-driven oncogenesis in ALL. To investigate whether E2A-PBX1 can be acetylated by GCN5, we co-transfected HEK-293 cells with plasmids expressing E2A-PBX1a and FLAG-GCN5. We also included p300-HA in this experiment. E2A-PBX1a was immunoprecipitated from whole-cell extracts and acetylated E2A-PBX1 was detected by immunoblotting using an antibody, which recognizes acetylated lysines in E2A-PBX1. As shown in Figure 1c , acetylation of E2A-PBX1 was strongly enhanced in the presence of both GCN5 and also, as expected, p300 (lanes 2 and 3). Interestingly, coexpression of E2A-PBX1a with the HATs dramatically increased the protein levels of E2A-PBX1 (compare the inputs in lane 1 to lanes 2 and 3), indicating that acetylation of E2A-PBX1 may increase protein stability. Next, we determined whether E2A-PBX1 physically interacted with GCN5, and the LDFS motif in GCN5, and incubated recombinant GST, GST-E2A-PBX1a or GST-E2A-PBX1a-LDFSmut (GST-E2A-PBX1a-LAAS) affinity-purified proteins (Figure 1d ) with 35 S-labeled GCN5. As shown in Figure 1e , GCN5 interacted with GST-E2A-PBX1 (lane 3), but not significantly with GST-E2A-PBX1a-LDFSmut or the GST-negative control (lanes 2 and 4).
E2A-PBX1 interacts with the GCN5-containing STAGA complex
In vivo, GCN5 functions as part of the multi-subunit STAGA complex; therefore, we investigated the interaction between GST pull-down assays of GST-E2A-PBX1 or GST bound to glutathione-sepharose beads and the purified STAGA complex. The beads were subjected to the nucleosomal HAT assay; histone acetylation indicated the presence of STAGA. The input represents 30% of the purified STAGA used in each binding reaction. (e) Immobilized GST-E2A-PBX1 and bound STAGA were subjected to crosslinking with dithiobis (succinimidylpropionate) and crosslinking of the STAGA subunits GCN5, TAF31 and SPT3 was monitored by immunoblotting. The input represents 30% of the purified STAGA or 5% of nuclear extract used in each binding reaction.
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E2A-PBX1 and the STAGA complex. STAGA was affinity purified using M2-agarose from a FLAG-SPT3-expressing cell line (Figure 2a) . GST pull-down assays were performed by incubating purified GST-tagged E2A-PBX1a, E2A or PBX1a fusion proteins with purified STAGA (Figure 2b ) or HeLa nuclear extracts (Figure 2d) , and the proteins were detected by immunoblotting with antibodies specific for the STAGA subunits, as indicated in Figure 2 . All of the STAGA subunits examined bound to GST-E2A and GST-E2A-PBX1, but not to GST-PBX1 or GST alone, indicating that STAGA directly associates with the E2A portion of E2A-PBX1. However, it should be noted that we detected a weak interaction between GST-PBX1 and TAF31 using affinity purified STAGA, but no interaction in HeLa nuclear extract. None of the GST-tagged proteins bound to CDK11 (a subunit in the Mediator complex), further indicating the interaction between E2A and STAGA was specific.
In a subsequent GST pull-down assay with GST-E2A-PBX1a and purified STAGA, the beads were subjected to a nucleosomal HAT assay using [ 3 H]-acetyl-CoA. The reaction products were separated by SDS-PAGE and visualized by autoradiography. Strong acetylation of histone H3, and to a lesser extent H4, was detected in the input and GST-E2A-PBX1 fraction, indicating that E2A-PBX1 recruits enzymatically active STAGA (Figure 2c ). To further characterize the interaction between E2A-PBX1 and STAGA, immobilized GST-E2A-PBX1 and bound purified STAGA or HeLa nuclear extract were subjected to crosslinking with dithiobis (succinimidylpropionate). As shown in Figure 2e , GCN5, as part of the STAGA complex, strongly interacted with GST-E2A-PBX1, while other STAGA subunits (SPT3 and TAF31) showed no significant crosslinking with GST-E2A-PBX1.
The GCN5 inhibitor MB-3 decreases acetylation and induces degradation of E2A-PBX1 The a-methylene-g-butyrolactone 3 (MB-3) is a small, cell-permeable GCN5 inhibitor with an IC 50 of 100 mM, 28 which can reduce the The amount of acetylated E2A-PBX1 was determined by densitometric analysis of the scanned films, and expressed relative to the total levels of E2A-PBX1 in the IP fraction using Image J software. The data were derived from the experiment in (a). (c) RCH-ACV, 697 and REH cells were treated with the GCN5 inhibitor MB-3 for 16 h as indicated. E2A-PBX1 protein was immunoprecipitated from whole-cell extracts and acetylation of endogenous E2A-PBX1 was monitored by immunoblot using an antibody recognizing acetylated lysines. REH cells, which do not express E2A-PBX1, were used as a negative control. The input represents 5% of the whole-cell extracts used in each binding reaction. (d) RCH-ACV cells were treated for 14 h with 0, 50 or 100 mM MB-3 and the whole-cell extracts were analyzed by immunoblotting with the indicated antibodies. (e) Leukemic cells from a patient carrying the t(1;19) translocation were isolated, treated with 50 mM MB-3 for 14 h, then analyzed by western blotting using the indicated antibodies. (f ) RCH-ACV cells were pre-treated with 100 mM MB-3 for 2 h and protein synthesis was inhibited with cycloheximide at the times indicated. Degradation of E2A-PBX1 protein was monitored by immunoblotting and the bands were quantified using Image J software. The data in the plots are derived from six independent experiments.
E2A-PBX1 is acetylated by GCN5 T Holmlund et al acetylation of both histone (H3) and non-histone (a-tubulin) substrates. 29 As we discovered that GCN5 acetylates E2A-PBX1, we examined the effect of MB-3 on E2A-PBX1 acetylation. HEK-293 cells were co-transfected with plasmids expressing E2A-PBX1a and FLAG-GCN5, and subsequently cultured in the presence of MB-3. We detected a strong dose-dependent reduction in the levels of acetylated E2A-PBX1 in cells treated with MB-3 (Figure 3a , compare lane 3 with lanes 4 and 5). MB-3 also lead to a decrease in E2A-PBX1 protein levels (Figure 3a, top panel) ; therefore, we quantified the relative amounts of acetylated E2A-PBX1 and immunoprecipitated E2A-PBX1, and observed that MB-3 induced a 60% reduction in E2A-PBX1 acetylation (Figure 3b) . The RCH-ACV and 697 cell lines are derived from the bone marrow cells of a patient with pre-B-cell ALL and carries the t(1;19)(q23;p13.3) translocation; thus, these cells endogenously express the E2A-PBX1 fusion protein. The RCH-ACV and 697 cell lines were used to detect acetylation of endogenous E2A-PBX1 and the REH cell line that does not contain the E2A-PBX1 translocation was used as a negative control. Whole-cell extracts were prepared from the cell lines and E2A-PBX1 immunoprecipitated with an antibody recognizing E2A-PBX1. Immunoblotting with an antibody recognizing acetylated lysines detected acetylation of endogenous E2A-PBX1 in both RCH-ACV and 697 cell lines, and E2A-PBX1 acetylation was inhibited by MB-3 (Figure 3c , compare lanes 1 and 5 with lanes 2 and 6).
Next, we treated RCH-ACV cells with increasing concentrations of MB-3, and observed a strong dose-dependent reduction in the protein levels of E2A-PBX1 and E2A (Figure 3d) . We also observed a reduction in Wnt16, an E2A-PBX1 target gene, which has been suggested to be of importance for oncogenesis in t(1;19)-positive pre-B leukemia, 10 in RCH-ACV cells cultured with MB-3. MB-3 also decreased the protein levels of GCN5. In addition, pre-B ALL cells were isolated from a patient carrying the t(1;19) translocation and treated with 50 mM MB-3. Consistent with RCH-ACV cells, we detected a significant reduction in the levels of E2A-PBX1, E2A and Wnt16; while the levels of GCN5 were only slightly reduced (Figure 3e) . The protein expression levels of Tubulin and Pol II were not affected by MB-3 (Figures 3d and e) , indicating that MB-3 may reduce the stability of specific proteins, which we suggest may be due to an inhibition of protein acetylation by GCN5 (Figure 3a) . To investigate whether GCN5-dependent acetylation affect E2A-PBX1 protein half-life, RCH-ACV cells were cultured in the presence of 100 mM MB-3, 10 mM TSA and 20 mM nicotinamide for 2 h before treatment with 100 mg/ml cycloheximide for 2, 4 and Whole-cell extracts were prepared and FLAG-PBX1 was affinity purified using M2-agarose. Ubiquitination of PBX1 was analyzed by immunoblotting using an antibody, which recognizes the FLAG-tag. (f) REH cells were transfected with plasmids expressing E2A-PBX1a (top panel) or E2A-PBX1b (bottom panel) and HDM2, whole-cell extracts were prepared and E2A-PBX1 was detected by immunoblotting. (g) HEK-293 cells were transfected with plasmids expressing E2A-PBX1 and HDM2 where indicated, and after 48 h cells were treated with cycloheximide. Degradation of E2A-PBX1 protein was detected by immunoblotting.
E2A-PBX1 is acetylated by GCN5 T Holmlund et al 6 h, respectively. The levels of E2A-PBX1 protein were detected by western blot with an antibody recognizing E2A-PBX1 and presented in a graph by quantifying the bands with Image J software (National Institutes of Health, Bethesda, MD, USA) ( Figure 3f ). The E2A-PBX1 half-life was 10 h in the absence of MB-3, while E2A-PBX1 half-life was 6 h in cells cultured with MB-3, further suggesting GCN5 acetylation regulates E2A-PBX1 stability.
HDM2 ubiquitinates E2A-PBX1 Ubiquitination affects the stability of many cellular proteins; therefore, we investigated whether E2A-PBX1 is a target of ubiquitination. Whole-cell extracts from RCH-ACV cells were subjected to immunoprecipitation with antibodies recognizing E2A-PBX1 and E3 ligases. HDM2 is an ubiquitin E3 ligase that promotes ubiquitination of itself, p53 and several other cellular proteins, which leads to proteasomal degradation. 23 As shown in Figure 4a , immunoprecipitated HDM2 interacted strongly with E2A-PBX1 (top panel); whereas there was only a faint interaction between HDM2 and E2A (bottom panel). The E2A antibody used in the bottom panel of Figure 4a recognizes both E2A and E2A-PBX1, while the E2A-PBX1 antibody used in the top panel is specific for only E2A-PBX1. We also performed in vitro protein interaction assays using GST-tagged E2A-PBX1b, E2A, PBX1a or PBX1b. The GST-tagged proteins ( Figure 4b ) were incubated with recombinant affinitypurified His-HDM2, and interacting HDM2 was detected by western blotting. In agreement with Figure 4a , HDM2 interacted strongly with E2A-PBX1 and PBX1, but less strongly with E2A ( Figure 4c) .
In order to evaluate the ability of HDM2, to mediate E2A-PBX1 ubiquitination, we co-transfected HEK-293 cells with E2A-PBX1a, HAUbiquitin and FLAG-HDM2. E2A-PBX1 was immunoprecipitated from whole-cell extracts and in vivo ubiquitination of E2A-PBX1 was analyzed by immunoblotting using an anti-HA antibody. The data showed ubiquitination of E2A-PBX1, and HDM2 overexpression further enhanced E2A-PBX1 ubiquitination (Figure 4d, lanes 2 and 4) . When monitoring PBX1 ubiquitination in a similar experiment, the effect of HDM2 on PBX1 ubiquitination was even more pronounced, compared with E2A-PBX1 ubiquitination (Figure 4e) . To assess the effect of HDM2 on the stability of E2A-PBX1, we co-expressed E2A-PBX1 and HDM2 in REH leukemic pre-B ALL cells, and observed that HDM2 markedly reduced the levels of E2A-PBX1 protein (Figure 4f ). In addition, HEK-293 cells were transfected with E2A-PBX1 and HDM2 expression plasmids and treated with cycloheximide for 1 and 2 h, respectively. Consistently, the level of E2A-PBX1 was decreased in the presence of HDM2 (Figure 4g, compare lanes 1 and 4) . After incubation with cycloheximide, less E2A-PBX1 protein was present in cells transfected with HDM2, compared with cells without overexpressed HDM2 (lanes 2-3 and 5-6) and a 15% reduction in E2A-PBX1 half-life was estimated. In summary, these results indicate that HDM2 mediates ubiquitination of E2A-PBX1, via interacting with the PBX1 domain, which may potentiate the degradation of E2A-PBX1.
DISCUSSION
It was recently reported that the LDFS motif of the E2A AD1 is required for E2A-PBX1 to induce fibroblast proliferation in cell culture. 16 The LDFS motif is known to interact with SAGA, 15 the yeast homolog of the human STAGA complex, of which the GCN5 subunit possesses acetyl transferase activity. In this report we show, for the first time, that E2A-PBX1 directly interacts with human GCN5 and STAGA, and we demonstrate that E2A-PBX1 is acetylated by GCN5.
Protein acetylation, in addition to a variety of other covalent post-translational modifications, can affect various aspects of protein function, including folding, enzymatic activity, localization and stability. In this study we demonstrated that acetylation of the chimeric E2A-PBX1 protein increased E2A-PBX1 protein levels in cells transfected with E2A-PBX1 and GCN5 expression plasmids (Figure 1 ). In agreement with this observation, the GCN5 inhibitor MB-3 reduced E2A-PBX1 acetylation and decreased E2A-PBX1 protein half-life in ALL cells (Figure 3) . These results strongly suggest that acetylation increases the stability of E2A-PBX1, which may contribute to its oncogenic properties by increasing the activation of specific E2A-PBX1 target genes. Interestingly, we noted that the E2A-PBX1 acetylation status correlated with the protein levels of the E2A-PBX1 target gene WNT16. Treatment of ALL cells with the GCN5 inhibitor MB-3 also lead to a small reduction in GCN5 protein levels (Figure 3 ). This effect may possibly be due to the interference of MB-3 with acetyl-CoA binding, which has been shown to stabilize GCN5. 30 Another possible explanation is that MB-3 may affect GCN5 autoacetylation. Autoacetylation increases acetyltransferase activity and protein stability, and has been described both for p300 and PCAF; [31] [32] [33] however, to our knowledge, not yet for GCN5.
In addition to GCN5, we found that the ubiquitin E3 ligase HDM2 potentially has a role in the stability of E2A-PBX1. HDM2 mediated ubiquitination and potentiated degradation of E2A-PBX1. Our results suggest that HDM2 interacts with the PBX1 domain of E2A-PBX1, and also that the E2A domain is responsible for the STAGA/GCN5 interaction. In the model depicted in Figure 5 , we propose that E2A-PBX1 protein stability may be regulated by (at least) two post-translational modifications. The STAGA/GCN5 interaction and protein acetylation of the E2A domain increase E2A-PBX1 stability; whereas the interaction with HDM2 and ubiquitination of the PBX1 domain result in protein degradation. These modifications are thought to occur within different regions of the E2A-PBX1 molecule; therefore, acetylation and ubiquitination enzymes would not be expected to compete for the same amino acids. In agreement with this model, we could not detect any effect of GCN5 on the ubiquitination of E2A-PBX1 (data not shown). It, however, remains to be investigated whether E2A-PBX1 lysine acetylation is a post-translational protein modification rivaling ubiquitination by E3 ligases other than HDM2, or if acetylation might occur in competition with modifications such as SUMOylation and/or phosphorylation.
Due to improvements in treatment strategies in recent decades, the survival rate of pediatric ALL has increased immensely and is currently B80%.
1 Despite the overall good prognosis, there remains a large group of children who suffer disease relapse, and many patients suffer from the severe side effects of chemotherapeutic agents. In addition, some subtypes of ALL are associated with a higher risk of relapse, including t(1;19) E2A-PBX1-positive ALL. 4 Drugs that target epigenetic modifications are promising agents for the treatment of several human pathologies. Histone deacetylase inhibitors are the most characterized, with at least two compounds already approved for the treatment of cutaneous T-cell lymphoma. 34, 35 The investigation of HAT inhibitors is a growing area of interest, and holds promise for the treatment of cancer, as well as diabetes and neurological disorders including Alzheimer's disease. 36 Interestingly, we found that the GCN5 inhibitor MB-3 strongly reduced E2A-PBX1 protein levels in primary leukemic cells and a E2A-PBX1 is acetylated by GCN5 T Holmlund et al pre-B ALL cell line. We suggest that this effect is mediated via reduced acetylation of E2A-PBX1, which may reduce E2A-PBX1 protein stability. Although leukemogenesis is a multi-step process, and secondary genetic events may be required for leukemic transformation in addition to the t(1;19) translocation, the role of E2A-PBX1 in pre-B-cell transformation is well established ( 3 and references within). Therefore, reducing the protein levels of E2A-PBX1 in pre-B cells is an appealing therapeutic strategy. We demonstrated that E2A-PBX1 protein levels can be reduced using the GCN5 inhibitor MB-3. Naturally, inhibition of GCN5 will also affect global, as well as locus-specific, histone acetylation along with a vast number of non-histone GCN5 targets, and potentially result in side effects. GCN5 has a crucial role in a wide range of biological processes and is indispensable for the normal function of cells. Therefore, the effect of MB-3 must be thoroughly investigated in further E2A-PBX1 models as well as in normal cells and in toxicity animal studies. The challenge for future ALL treatments is the design of selective inhibitors that target only cancer cells, without affecting normal cells. Further investigation may reveal if MB-3, or derivatives of this compound, may be of value as a therapeutic agent for pre-B ALL.
